CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The firm mainly conducts its business in the domestic market.
根據最新的財務報表(Form-10K),International Media Acquisition Corp 的總資產為 $0,淨isProfitable}為 $0
CASI 的關鍵財務比率是什麼?
International Media Acquisition Corp 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
CASI Pharmaceuticals Inc 的收入按細分市場或地理位置如何劃分?
International Media Acquisition Corp 最大收入來源為 Humate-based Trace Element Fertilizers and Animal Feed Products,在最近的收益報告中收入為 2,776,667。就地區而言,United States 是 International Media Acquisition Corp 的主要市場,收入為 2,776,667。
CASI Pharmaceuticals Inc 是否盈利?
無,根據最新的財務報表,International Media Acquisition Corp 的淨損失為 $0